AR122183A2 - Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato - Google Patents

Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato

Info

Publication number
AR122183A2
AR122183A2 ARP210101431A ARP210101431A AR122183A2 AR 122183 A2 AR122183 A2 AR 122183A2 AR P210101431 A ARP210101431 A AR P210101431A AR P210101431 A ARP210101431 A AR P210101431A AR 122183 A2 AR122183 A2 AR 122183A2
Authority
AR
Argentina
Prior art keywords
crystalline form
solvate
inhalation
pharmaceutical composition
preparation
Prior art date
Application number
ARP210101431A
Other languages
English (en)
Inventor
Alessandro Falchi
Emilio Lutero
Emanuele Ferrari
Fausto Pivetti
Rocco Bussolati
Edoardo Mariani
Orsola Vecchi
Erhard Bappert
Caterina Ventrici
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR122183(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR122183A2 publication Critical patent/AR122183A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Proceso para preparar una forma cristalina de un compuesto de fórmula (1) donde n es 1 y donde la cantidad total de impurezas fácilmente detectables en la forma cristalina del compuesto de fórmula (1) es menos de 5% p/p y el porcentaje de cristalinidad es igual o superior a 90%, que comprende calentar una suspensión del compuesto de fórmula (1) junto con acetato de etilo / n-heptano o acetato de isopropilo, a una temperatura entre 50 - 90ºC hasta la disolución del sólido, enfriar la suspensión entre 0 - 5ºC durante 1 - 5 horas, filtrar y secar; forma cristalina; composición farmacéutica para inhalación; usos; y solvato.
ARP210101431A 2013-10-22 2021-05-27 Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato AR122183A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22

Publications (1)

Publication Number Publication Date
AR122183A2 true AR122183A2 (es) 2022-08-24

Family

ID=49385193

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103938A AR098128A1 (es) 2013-10-22 2014-10-20 Proceso para la preparación de un inhibidor de pde4
ARP200100438A AR118124A2 (es) 2013-10-22 2020-02-17 Proceso para la preparación de un inhibidor de pde4
ARP210101431A AR122183A2 (es) 2013-10-22 2021-05-27 Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato
ARP210101430A AR122182A2 (es) 2013-10-22 2021-05-27 Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP140103938A AR098128A1 (es) 2013-10-22 2014-10-20 Proceso para la preparación de un inhibidor de pde4
ARP200100438A AR118124A2 (es) 2013-10-22 2020-02-17 Proceso para la preparación de un inhibidor de pde4

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101430A AR122182A2 (es) 2013-10-22 2021-05-27 Procesos para la preparación de compuestos intermediarios de un inhibidor de pde4 y dichos compuestos intermediarios

Country Status (29)

Country Link
US (7) US9434691B2 (es)
EP (5) EP3060551B1 (es)
JP (5) JP6458957B2 (es)
KR (3) KR102240865B1 (es)
CN (5) CN110256338A (es)
AR (4) AR098128A1 (es)
AU (1) AU2014339136C1 (es)
BR (1) BR112016008161B1 (es)
CA (3) CA3115587C (es)
CY (1) CY1123811T1 (es)
DK (3) DK3293176T3 (es)
ES (3) ES2980505T3 (es)
FI (1) FI3587400T3 (es)
HR (3) HRP20240783T1 (es)
HU (3) HUE067681T2 (es)
IL (4) IL285532B2 (es)
LT (2) LT3587400T (es)
MX (4) MX370104B (es)
MY (1) MY182559A (es)
PH (3) PH12020500162B1 (es)
PL (3) PL3587400T3 (es)
PT (3) PT3587400T (es)
RS (2) RS61558B1 (es)
RU (1) RU2682660C9 (es)
SG (4) SG10201903575UA (es)
SI (3) SI3060551T1 (es)
TW (3) TWI685486B (es)
UA (2) UA121853C2 (es)
WO (1) WO2015059050A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3246016T3 (da) 2010-08-03 2025-05-19 Chiesi Farm Spa Tørpulverformulering indeholdende en fosfodiesterasehæmmer
SI3060551T1 (sl) * 2013-10-22 2019-11-29 Chiesi Farm Spa Postopek za pripravo inhibitorja PDE4
WO2018017713A1 (en) * 2016-07-20 2018-01-25 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
AU2023262106A1 (en) 2022-04-27 2024-12-05 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
KR20250069950A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기
PE20251716A1 (es) 2022-09-22 2025-07-07 Chiesi Farm Spa Inhalador de capsula para la administracion de un inhibidor de fosfodiesterasa-4
EP4590272A1 (en) 2022-09-22 2025-07-30 Chiesi Farmaceutici S.p.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
KR102925863B1 (ko) 2023-11-27 2026-02-09 국립한국해양대학교산학협력단 복수의 학습모델을 이용한 이미지 기반의 강도 추정 장치 및 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU2001239442A1 (en) * 2000-03-30 2001-10-15 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
WO2005026095A1 (en) 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
ATE459618T1 (de) * 2004-04-29 2010-03-15 Aventis Pharma Inc 3-piperidinylisochroman-5-ole als dopaminagonisten
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
EP2125736B1 (en) * 2006-12-22 2011-03-30 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
ES2528957T3 (es) 2010-06-14 2015-02-13 Chiesi Farmaceutici S.P.A. Forma cristalina del cloruro de glicopirronio
DK3246016T3 (da) * 2010-08-03 2025-05-19 Chiesi Farm Spa Tørpulverformulering indeholdende en fosfodiesterasehæmmer
CA2807406C (en) * 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
CN103827088B (zh) * 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
KR102192739B1 (ko) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CN103304408B (zh) * 2013-06-05 2016-10-05 威海迪素制药有限公司 罗氟司特中间体3-环丙甲氧基-4-二氟甲氧基苯甲酸的制备
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
SI3060551T1 (sl) * 2013-10-22 2019-11-29 Chiesi Farm Spa Postopek za pripravo inhibitorja PDE4
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
BR112020012972A2 (pt) * 2017-12-28 2020-11-24 Chiesi Farmaceutici S.P.A. uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
EP4452223A1 (en) * 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Also Published As

Publication number Publication date
CN105658629B (zh) 2019-07-16
PL3060551T3 (pl) 2020-03-31
ES2759514T3 (es) 2020-05-11
US10323003B2 (en) 2019-06-18
HK1223926A1 (zh) 2017-08-11
ES2980505T3 (es) 2024-10-01
KR20210021416A (ko) 2021-02-25
CA3115570C (en) 2024-01-30
JP7345581B2 (ja) 2023-09-15
AR118124A2 (es) 2021-09-22
IL285528A (en) 2021-09-30
EP3060551A1 (en) 2016-08-31
TW201605804A (zh) 2016-02-16
MY182559A (en) 2021-01-25
EP3060551B1 (en) 2019-09-18
JP7051970B2 (ja) 2022-04-11
IL245220A (en) 2017-06-29
IL252834A0 (en) 2017-08-31
KR102287598B1 (ko) 2021-08-11
PL3587400T3 (pl) 2024-07-01
RU2016115246A3 (es) 2018-06-27
SI3293176T1 (sl) 2021-04-30
IL285528B2 (en) 2025-09-01
EP3293176A1 (en) 2018-03-14
US20190345108A1 (en) 2019-11-14
PH12016500737A1 (en) 2016-05-30
PT3060551T (pt) 2019-12-09
FI3587400T3 (fi) 2024-06-20
KR20160072127A (ko) 2016-06-22
US9890122B2 (en) 2018-02-13
KR20210021415A (ko) 2021-02-25
RU2682660C2 (ru) 2019-03-20
TWI685486B (zh) 2020-02-21
PL3293176T3 (pl) 2021-06-28
AR122182A2 (es) 2022-08-24
DK3293176T3 (da) 2021-02-15
US11352327B2 (en) 2022-06-07
CN114621139A (zh) 2022-06-14
HUE046637T2 (hu) 2020-03-30
EP3587400B1 (en) 2024-03-20
TWI651305B (zh) 2019-02-21
UA121853C2 (uk) 2020-08-10
PT3587400T (pt) 2024-06-05
US10759761B2 (en) 2020-09-01
MX370104B (es) 2019-12-02
KR102287596B1 (ko) 2021-08-11
PH12016500737B1 (en) 2022-03-23
CA3115570A1 (en) 2015-04-30
PH12020500162A1 (en) 2021-08-02
US20150111931A1 (en) 2015-04-23
UA127453C2 (uk) 2023-08-30
US20180118686A1 (en) 2018-05-03
WO2015059050A1 (en) 2015-04-30
EP4059921A1 (en) 2022-09-21
US9434691B2 (en) 2016-09-06
SG10201912852YA (en) 2020-02-27
BR112016008161B1 (pt) 2022-11-29
IL285532A (en) 2021-09-30
HRP20210336T1 (hr) 2021-04-16
HUE067681T2 (hu) 2024-11-28
JP2019038813A (ja) 2019-03-14
CN114621139B (zh) 2025-06-20
SG11201603130TA (en) 2016-05-30
HRP20240783T1 (hr) 2024-09-27
DK3060551T3 (da) 2019-10-28
BR112016008161A2 (es) 2017-08-01
CA3115587A1 (en) 2015-04-30
EP3293176B1 (en) 2020-12-02
RU2016115246A (ru) 2017-11-27
IL285532B2 (en) 2024-03-01
AR098128A1 (es) 2016-05-04
JP2021011494A (ja) 2021-02-04
MX2022000030A (es) 2022-07-19
LT3587400T (lt) 2024-04-25
SG10201903575UA (en) 2019-05-30
IL285528B1 (en) 2025-05-01
CN120136784A (zh) 2025-06-13
RS65452B1 (sr) 2024-05-31
LT3293176T (lt) 2021-03-25
EP3587400A3 (en) 2020-03-25
MX389002B (es) 2025-03-20
JP7534346B2 (ja) 2024-08-14
EP3587400A2 (en) 2020-01-01
KR102240865B9 (ko) 2021-12-13
CA2928242A1 (en) 2015-04-30
SI3060551T1 (sl) 2019-11-29
CA3115587C (en) 2026-01-06
HUE053112T2 (hu) 2021-06-28
CN120607463A (zh) 2025-09-09
KR102240865B1 (ko) 2021-04-16
TWI720803B (zh) 2021-03-01
JP2017505752A (ja) 2017-02-23
SI3587400T1 (sl) 2024-05-31
MX2016004834A (es) 2016-07-19
DK3587400T3 (da) 2024-04-02
CN105658629A (zh) 2016-06-08
IL252834B (en) 2021-09-30
IL285532B1 (en) 2023-11-01
TW201904945A (zh) 2019-02-01
JP6458957B2 (ja) 2019-01-30
JP2022068321A (ja) 2022-05-09
US20240166605A1 (en) 2024-05-23
RS61558B1 (sr) 2021-04-29
PH12021550257A1 (en) 2023-01-23
PT3293176T (pt) 2021-03-03
SG10202112587RA (en) 2021-12-30
CA2928242C (en) 2022-03-15
US11981639B2 (en) 2024-05-14
US20160326117A1 (en) 2016-11-10
US20210040040A1 (en) 2021-02-11
US20220348545A1 (en) 2022-11-03
MX2019014408A (es) 2020-01-27
AU2014339136B2 (en) 2018-05-31
CY1123811T1 (el) 2022-05-27
PH12020500162B1 (en) 2024-06-14
AU2014339136C1 (en) 2019-10-31
ES2857629T3 (es) 2021-09-29
JP2022071008A (ja) 2022-05-13
IL245220A0 (en) 2016-06-30
EP3798209A1 (en) 2021-03-31
CN110256338A (zh) 2019-09-20
TW202021952A (zh) 2020-06-16
RU2682660C9 (ru) 2019-06-21
MX2022000036A (es) 2022-07-19
HRP20192152T1 (hr) 2020-02-21

Similar Documents

Publication Publication Date Title
AR122183A2 (es) Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
NZ716840A (en) Combination formulation of two antiviral compounds
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IN2014DN09352A (es)
CL2017001377A1 (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
IN2014DN09348A (es)
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
EA201600434A1 (ru) Применение производных бензимидазолпролина
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
IN2014DN09347A (es)
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
MY169064A (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
BR112015022859A2 (pt) processo para fabricação de mono-hidrato trissódico gadofosveset
HK1217333A1 (zh) 喹唑啉衍生物的固態形式及其作爲braf抑制劑的用途
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2014108337A8 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Legal Events

Date Code Title Description
FB Suspension of granting procedure